Here are the latest Venture Case winners: PharmaBiome and SIMPLInext
22.09.2015
PharmaBiome and SIMPLInext won the second stage of Venture Kick and its CHF 20’000 of pre-seed capital. They are now boosting their business plan for the final.
 Tomas de Wouters from PharmaBiome
|
 |
 The SIMPLInext team
|
|
PharmaBiome will develop an innovative technology platform to formulate safe, efficient and scalable pharma-level fecal microbiota transplant products. Fecal microbiota transplant is a novel, lifesaving therapy that has no approved pharmacological solution yet. Our technology will address this need and extend its use from last resort treatment of infections to the treatment and prevention of multiple other microbiota related diseases.
SIMPLInext markets the next generation of consumable labware for the design of early stage toxicity testing.
SIMPLInext markets the next generation of consumable labware for the design of early stage toxicity testing.